Biovica International AB Stock Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
Apr. 13 | Certain B Shares of Biovica International AB are subject to a Lock-Up Agreement Ending on 13-APR-2024. | CI |
Apr. 12 | Biovica International AB Announces Divitum® Tka in Observational Trial | CI |
Sales 2024 * | 10M 925K | Sales 2025 * | 116M 10.73M | Capitalization | 139M 12.83M |
---|---|---|---|---|---|
Net income 2024 * | -115M -10.64M | Net income 2025 * | -60M -5.55M | EV / Sales 2024 * | 6.52 x |
Net cash position 2024 * | 73.52M 6.8M | Net cash position 2025 * | 45.95M 4.25M | EV / Sales 2025 * | 0.8 x |
P/E ratio 2024 * |
-0.22
x | P/E ratio 2025 * |
-0.58
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.54% |
Latest transcript on Biovica International AB
Managers | Title | Age | Since |
---|---|---|---|
Anders Rylander
CEO | Chief Executive Officer | 54 | 09-12-31 |
Anders Morén
DFI | Director of Finance/CFO | 59 | 22-12-31 |
Hanna Ritzen
CTO | Chief Tech/Sci/R&D Officer | 45 | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 64 | 19-03-19 | |
Annika Berg
BRD | Director/Board Member | 61 | 19-12-31 |
Maria Holmlund
BRD | Director/Board Member | 68 | 15-12-31 |
1st Jan change | Capi. | |
---|---|---|
-14.37% | 11.41B | |
+70.73% | 3.81B | |
-29.39% | 2.3B | |
-12.90% | 2.16B | |
+37.56% | 1.19B | |
-2.40% | 760M | |
-15.17% | 506M | |
-34.29% | 444M | |
+13.72% | 339M |